87 related articles for article (PubMed ID: 38468323)
1. Pre-treatment peripheral blood immunophenotyping and response to neoadjuvant chemotherapy in operable breast cancer.
Leon-Ferre RA; Whitaker KR; Suman VJ; Hoskin T; Giridhar KV; Moore RM; Al-Jarrad A; McLaughlin SA; Northfelt DW; Hunt KN; Conners AL; Moyer A; Carter JM; Kalari K; Weinshilboum R; Wang L; Ingle JN; Knutson KL; Ansell SM; Boughey JC; Goetz MP; Villasboas JC
Breast Cancer Res; 2024 Jun; 26(1):97. PubMed ID: 38858721
[TBL] [Abstract][Full Text] [Related]
2. Cell-free DNA Concentration as a Biomarker of Response and Recurrence in HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy.
Magbanua MJM; Ahmed Z; Sayaman RW; Brown Swigart L; Hirst GL; Yau C; Wolf DM; Li W; Delson AL; Perlmutter J; Pohlmann P; Symmans WF; Yee D; Hylton NM; Esserman LJ; DeMichele AM; Rugo HS; van 't Veer LJ
Clin Cancer Res; 2024 Jun; 30(11):2444-2451. PubMed ID: 38470545
[TBL] [Abstract][Full Text] [Related]
3. Tumor infiltrating lymphocytes (TILs) are a prognosis biomarker in Colombian patients with triple negative breast cancer.
Huertas-Caro CA; Ramírez MA; Rey-Vargas L; Bejarano-Rivera LM; Ballen DF; Nuñez M; Mejía JC; Sua-Villegas LF; Cock-Rada A; Zabaleta J; Fejerman L; Sanabria-Salas MC; Serrano-Gomez SJ
Sci Rep; 2023 Dec; 13(1):21324. PubMed ID: 38044375
[TBL] [Abstract][Full Text] [Related]
4. Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.
Chalakur-Ramireddy NKR; Pakala SB
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29298879
[TBL] [Abstract][Full Text] [Related]
5. Assessment of stromal tumor-infiltrating lymphocytes in neoadjuvant chemotherapy for invasive breast carcinoma: Predictive insights across molecular subtypes.
Khan AA; Ahuja S; Kiruthikasri K; Zaheer S
Pathol Res Pract; 2024 May; 260():155382. PubMed ID: 38850879
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy.
Yoneyama M; Zormpas-Petridis K; Robinson R; Sobhani F; Provenzano E; Steel H; Lightowlers S; Towns C; Castillo SP; Anbalagan S; Lund T; Wennerberg E; Melcher A; Coles CE; Roxanis I; Yuan Y; Somaiah N
Int J Radiat Oncol Biol Phys; 2024 Apr; ():. PubMed ID: 38677525
[TBL] [Abstract][Full Text] [Related]
7. What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?
Forester E; Belsare A; Kim DW; Whitaker K; Obeid E; Goldstein LJ; Bleicher RJ; Daly MB; Williams AD
J Surg Res; 2024 May; 299():217-223. PubMed ID: 38776577
[TBL] [Abstract][Full Text] [Related]
8. Expression of CD28, FAS, PD1, and CTLA4 molecules in the blood of women with triple-negative breast cancer.
Salgado MRT; Sobral DV; Martins MR; Salgado EFMT; Salgado AFMT; Silva KRD; Soares FA; Torres LC
J Surg Oncol; 2024 Jun; ():. PubMed ID: 38845213
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients.
Hwang HW; Jung H; Hyeon J; Park YH; Ahn JS; Im YH; Nam SJ; Kim SW; Lee JE; Yu JH; Lee SK; Choi M; Cho SY; Cho EY
Breast Cancer Res Treat; 2019 Jan; 173(2):255-266. PubMed ID: 30324273
[TBL] [Abstract][Full Text] [Related]
10. Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Hudeček J; Voorwerk L; van Seijen M; Nederlof I; de Maaker M; van den Berg J; van de Vijver KK; Sikorska K; Adams S; Demaria S; Viale G; Nielsen TO; Badve SS; Michiels S; Symmans WF; Sotiriou C; Rimm DL; Hewitt SM; Denkert C; Loibl S; Loi S; Bartlett JMS; Pruneri G; Dillon DA; Cheang MCU; Tutt A; Hall JA; Kos Z; Salgado R; Kok M; Horlings HM;
NPJ Breast Cancer; 2020; 6():15. PubMed ID: 32436923
[TBL] [Abstract][Full Text] [Related]
11. HER2-low and tumor infiltrating lymphocytes in triple-negative breast cancer: Are they connected?
Baez-Navarro X; van den Ende NS; Nguyen AH; Sinke R; Westenend P; van Brakel JB; Stobbe C; Westerga J; van Deurzen CHM
Breast Cancer Res; 2024 Mar; 26(1):41. PubMed ID: 38468323
[TBL] [Abstract][Full Text] [Related]
12. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the Predictive and Prognostic Values of Stromal Tumor-Infiltrating Lymphocytes in HER2-Positive Breast Cancers treated with neoadjuvant chemotherapy.
Yang X; Rao J; Yang W; Shui R
Target Oncol; 2018 Dec; 13(6):757-767. PubMed ID: 30406444
[TBL] [Abstract][Full Text] [Related]
14. Relationship Between the Neutrophil to Lymphocyte Ratio, Stromal Tumor-infiltrating Lymphocytes, and the Prognosis and Response to Neoadjuvant Chemotherapy in Triple-negative Breast Cancer.
Pang J; Zhou H; Dong X; Wang S; Xiao Z
Clin Breast Cancer; 2021 Dec; 21(6):e681-e687. PubMed ID: 34001439
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
